Cardiogen
Khavinson tetrapeptide bioregulator targeting cardiac myocytes — studied for cardioprotection, post-infarction recovery, and age-related heart function decline.
🔬 Mechanism of Action
Cardiogen (Ala-Glu-Asp-Arg, AEDR) is a synthetic tetrapeptide bioregulator targeting cardiac myocytes, identified through systematic fractionation of heart tissue peptide pools at the Saint Petersburg Institute of Bioregulation and Gerontology.
Cardiogen modulates gene expression for (1) cardiac contractile proteins (myosin heavy chain, troponin I, titin), (2) mitochondrial biogenesis factors (PGC-1α, TFAM) that maintain the exceptional energy demands of cardiac muscle, and (3) anti-apoptotic pathways (Bcl-2, Akt) that protect cardiomyocytes under ischemic stress.
In experimental myocardial ischemia models, pre-treatment with Cardiogen reduced infarct size by 25-35% and preserved left ventricular ejection fraction. It is the synthetic counterpart to Chelohart (cardiac Cytomax extract).
Source: PMID: 15677927
📜Background & History
Cardiogen (AEDR) targets cardiomyocytes for cardiac tissue resilience.
🎯 Research Use Cases
- ✓Cardiac tissue support in aging
- ✓Post-infarction recovery protocols
- ✓Cardiovascular health maintenance
💉 Dosing Protocol
| Typical Dose | 10-20 mg/day (oral) or 1-2 mg SC |
| Frequency | 1× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
🧪 Reconstitution Example
⚠️Safety & Considerations
Standard Khavinson protocol. Can be combined with Chelohart (cardiac Cytomax extract) for comprehensive cardiac support.
⚡Interactions & Contraindications
Standard Khavinson protocol.
🔗Synergies & Common Stacks
Cardiogen (synthetic) + Chelohart (cardiac Cytomax) = layered cardiac bioregulator support.
Cardiogen (heart muscle) + Vesugen (vascular endothelium) = comprehensive cardiovascular protocol.